This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beldner, M. Articles by Chaudhary, U. B. Search for Related Content PubMed PubMed Citation Articles by Beldner, M. Articles by Chaudhary, U. B.

Genitourinary Cancer

Localized Palmar–Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib

Departments of ^aHematology/Oncology, ^bDermatology, and ^cMedicine, Medical University of South Carolina, Charleston, South Carolina, USA; ^dDermpath Diagnostics Maize Center for Dermatopathology, Mt. Pleasant, South Carolina, USA

Key Words. Cutaneous manifestations • Tyrosine kinase inhibitors • Dermatologic toxicity • Sorafenib Palmar–plantar erythrodysesthesia • Hand–foot syndrome

Correspondence: Matthew Beldner, M.D., Department of Hematology/Oncology, Medical University of South Carolina, 903 CSB, 96 Jonathan Lucas Street, Charleston, South Carolina 29425, USA. Telephone: 843-792-7834; Fax: 843-792-0644; e-mail: beldner{at}musc.edu

Disclosure: U.B.C. has acted as consultant to Amgen, Genentech, Wyeth, Bristol-Myers Squibb, and Novartis, and has performed contract work for Amgen and Bristol-Myers Squibb within the last 2 years. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

The development of multitargeted tyrosine kinase inhibitors has provided significant advances in the treatment of renal cell carcinoma. This case describes initial therapy for managing renal cell cancer with the administration of sorafenib, a multitargeted tyrosine kinase inhibitor. We report the development of localized palmar–plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy. Mild-to-moderate dermatologic toxicity from sorafenib has been well described in the literature. We also review the current knowledge and the proposed hypothesis for the development of cutaneous events related to tyrosine kinase inhibitors. This particular case represents a unique form of dermatologic toxicity to sorafenib that has not previously been described in the literature.

This article has been cited by other articles:

				B. Vincenzi, D. Santini, A. Russo, R. Addeo, F. Giuliani, L. Montella, S. Rizzo, O. Venditti, A. M. Frezza, M. Caraglia, et al. Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib Oncologist, January 1, 2010; 15(1): 85 - 92. [Abstract] [Full Text] [PDF]

				J. Mesarch, J. Rupp, and N. Zaidi New onset of multiple keratoacanthomas and palmoplantar hyperkeratosis caused by the treatment of metastatic renal cell carcinoma with a new generation multi-kinase inhibitor BMJ Case Reports, December 9, 2009; 2009(dec09_1): bcr0320091687 - bcr0320091687. [Abstract] [Full Text]

				M. E. Lacouture, L. M. Reilly, P. Gerami, and J. Guitart Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib Ann. Onc., November 1, 2008; 19(11): 1955 - 1961. [Abstract] [Full Text] [PDF]

				M. E. Lacouture, S. Wu, C. Robert, M. B. Atkins, H. H. Kong, J. Guitart, C. Garbe, A. Hauschild, I. Puzanov, D. T. Alexandrescu, et al. Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib Oncologist, September 1, 2008; 13(9): 1001 - 1011. [Abstract] [Full Text] [PDF]